Delivery of anti-migraine compounds through an inhalation route

A method of forming a lidocaine containing aerosol comprising:

• (a) heating a composition containing lidocaine coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of lidocaine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a verapamil containing aerosol comprising:

• (a) heating a composition containing verapamil coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of verapamil degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a diltiazem containing aerosol comprising:

• (a) heating a composition containing diltiazem coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of diltiazem degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a isometheptene containing aerosol comprising:

• (a) heating a composition containing isometheptene coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of isometheptene degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a lisuride containing aerosol comprising:

• (a) heating a composition containing lisuride coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the particles comprise less than 5 percent by weight of lisuride degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a drug containing aerosol comprising:

• (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, and
• wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a drug containing aerosol comprising:

• (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor;
• and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, and
• wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

A method of forming a drug containing aerosol comprising:

• (a) heating a composition containing the drug coated on a solid support to form a vapor, and
• (b) condensing the vapor to form a condensation aerosol comprising particles,
• wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride,
• wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and
• wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.